Clinical Trial Detail

NCT ID NCT01726738
Title LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult

Additional content available in CKB BOOST